Scienture (NASDAQ:SCNX) Stock Scheduled to Reverse Split on Monday, October 5th

Shares of Scienture Holdings, Inc. (NASDAQ:SCNX) are scheduled to reverse split on Monday, October 5th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 4th.

Scienture Stock Performance

Shares of SCNX stock traded down $0.08 on Thursday, hitting $0.18. The stock had a trading volume of 1,900,908 shares, compared to its average volume of 1,572,648. The stock’s 50 day moving average is $0.37 and its 200-day moving average is $0.38. Scienture has a 52-week low of $0.18 and a 52-week high of $2.60. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.04 and a quick ratio of 2.97.

Scienture (NASDAQ:SCNX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.96 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a research report on Monday, September 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Scienture has a consensus rating of “Hold” and a consensus price target of $1.50.

Hedge Funds Weigh In On Scienture

A hedge fund recently bought a new stake in Scienture stock. Susquehanna International Group LLP bought a new position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned 0.57% of Scienture as of its most recent filing with the Securities and Exchange Commission (SEC). 5.68% of the stock is owned by institutional investors and hedge funds.

About Scienture

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).